行情

EGRX

EGRX

Eagle制药
NASDAQ

实时行情|Nasdaq Last Sale

40.13
-2.33
-5.49%
盘后: 40.13 0 0.00% 16:56 03/27 EDT
开盘
41.64
昨收
42.46
最高
42.93
最低
39.97
成交量
12.83万
成交额
--
52周最高
64.94
52周最低
33.80
市值
5.49亿
市盈率(TTM)
40.38
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测EGRX价格均价为50.67,最高价位59.00,最低价为46.00。

EPS

EGRX 新闻

更多
  • Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 5天前
  • Eagle Pharma to buyback $160M stock
  • seekingalpha · 03/17 17:57
  • Eagle Pharmaceuticals Announces $160M Buyback, Which Replaces Existing Buyback
  • Reuters · 03/17 11:10
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

所属板块

制药
-0.41%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

EGRX 简况

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
展开

微牛提供Eagle Pharmaceuticals Inc(NASDAQ-EGRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的EGRX股票新闻,以帮助您做出投资决策。